Get the latest news on ANGLE stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on ANPCY performance

Latest ANGLE Stock News | OTC:ANPCY | Benzinga

ANGLE PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.

ANGLE PLC

News

Press Releases

Angle PLC Announces Parsortix Based PD-L1 Assay Showcased at AACR

Angle PLC Announces Research on HER2 Assay Kit Showcased at AACR

Angle PLC Announces HER2 Presentation at SABCS

Legal

Angle PLC Announces Trading Update

Angle PLC Announces Parsortix Used in Research Paper from ETH Zurich

Angle PLC Announces Analysis of CTC-DNA and ctDNA using Illumina assay

Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Angle PLC Announces Issue of LTIP Options and Share Options

Angle PLC Announces Results of Eisai Phase 2 pilot study

AEMD

ANPCF

ANPCY

ASPI

ATWT

BDRX

BENF

BIXT

BNRG

BOSC

CSE:HG

ELRRF

GOSS

GOVX

HDRSF

HGRAF

IMRN

IPWR

JAGX

LGVN

MESO

PBEGF

RGBP

SIGY

TSX:CNL

TSX:ELO

TSX:TXP

TSXV:HI

TSXV:WRLG

UCAR

USEG

WRLGF

XXII

ANGLE

<p>Under the terms of this agreement, worth &pound;550,000 to ANGLE, the Company will develop a CTC-based AR assay. Assay development will take place in the ANGLE&#39;s UK laboratories, with project completion expected in&nbsp;Q1&nbsp;2025. A successful development phase will demonstrate the importance of the Parsortix system in assessing the efficacy of prostate cancer therapeutics and offers the potential for long-term, ongoing business for the Company supporting clinical studies.</p>

ANGLE Inks Supplier Agreement with AstraZeneca To Develop A Parsortix-Based Androgen Receptor Detection Assay For Use In Prostate Cancer Studies

Comments

ANGLE Stock News

News

Latest ANGLE Stock News | OTC:ANPCY | Benzinga

Friday, May 03, 2024

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga